Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: Implications for the development of novel therapeutic strategies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Large B-Cell, Diffuse
  • Neoplasm Recurrence, Local
  • Salvage Therapy

abstract

  • Our data demonstrate that patients with recurrent DLBCL not responding to second-line chemotherapy demonstrate dismal outcomes. Trials of novel regimens should be prioritized as management strategies for these patients. Our data provide an important benchmark in the evaluation of the potential clinical value of such approaches.

publication date

  • June 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3816/CLML.2010.n.030

PubMed ID

  • 20511164

Additional Document Info

start page

  • 192

end page

  • 6

volume

  • 10

number

  • 3